Site Search
Professionals 298 results
Capabilities 71 results
Industry
Insurance plays an essential role in risk mitigation for financial services companies. As risks evolve, questions often arise concerning the scope of insurance coverage and the interpretation and application of policy provisions. Winston’s insurance lawyers provide companies with best-in-class advice, corporate and transactional counsel, and, if need be, litigation defense in high-stakes coverage disputes and class actions. We have achieved excellent outcomes for our clients in matters involving a wide variety of insurance policies and claims, including cybersecurity, travel, long-term care, and annuities, among others. Moreover, we have experience in emerging issues and industries, such as blockchain technology and artificial intelligence, both of which present insurers with a unique and complicated set of risks and opportunities.
Practice Area
For decades, Winston has represented a broad array of clients in the insurance industry, including some of the world’s largest and best-known insurers. Our prowess in and understanding of the insurance industry encompasses not only its products, practices, and services, but also the increasing challenges posed by a world increasingly characterized by a fast-evolving technological landscape as well as financial, political, and environmental instability. Accordingly, Winston’s lawyers are among the most sought-after in the industry—not only by companies currently facing high-stakes litigations and investigations, but by those looking to take preventive action now in order to mitigate and manage their risk in the future.
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Experience 42 results
Experience
|January 29, 2026
A team led by Justin Levy, Austin Leach, and Ben Popeck served as sell-side advisors to GenNx360 Capital Partners in the sale of its portfolio company, Precision Aviation Group, to VSE Corporation for a total upfront consideration of approximately $2.025 billion in cash and equity. PAG expects to generate approximately $615 million of adjusted revenue for the fiscal year ended December 31, 2025. Together, VSE and PAG will create a more diversified, globally scaled aviation aftermarket platform with broader technical capabilities and an expanded portfolio of proprietary repair and solutions content designed to strengthen customer support, extend asset life, and reduce total cost of ownership.
Experience
|June 12, 2025
Winston Serves as Lead Counsel to GCP Capital Partners in New Continuation Vehicle
Winston & Strawn served as legal counsel to GCP Capital Partners (GCP) in connection with the formation and closing of a single-asset continuation vehicle involving ALKEME Insurance. Led by the PE and Funds Group practices, the team advised GCP throughout the transaction which included substantial newly committed capital to fund portfolio company ALKEME’s continued growth (the single asset). The fund raise was backed by a syndicate of institutional investors where Apollo S3 served as the lead investor. The deal signals a growing trend: the strategic use of continuation vehicles to extend sponsors’ ownership in high-performing portfolio companies. This deal also reflects a broader narrative in middle-market private equity: firms that started small are now scaling rapidly, and they’re turning to sophisticated liquidity solutions to fuel that growth.
Experience
|April 23, 2025
Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination
Winston & Strawn represented Voyager Acquisition Corp. in its announced business combination agreement with VERAXA Biotech AG, a biopharmaceutical company developing next-generation antibody-based cancer therapies. The combination will result in VERAXA becoming a publicly traded company on Nasdaq under the ticker symbol “VERX”, with a pre-money equity valuation of $1.3 billion and up to $253 million in cash held in trust by Voyager. The transaction is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals.
Insights & News 1,630 results
Sponsorship
|March 22, 2026
Winston & Strawn Sponsors 38th Annual Roth Conference
Winston & Strawn is proud to sponsor the 38th Annual Roth Conference. This year, the program will feature one-on-one and small group meetings, analyst-selected fireside chats, industry keynotes, and panel discussions.
Global Trade & Foreign Policy Insights
|February 19, 2026
|9 Min Read
United States Issues Significant New Sanctions Relief for Venezuela’s Oil & Gas Sector
Although Venezuela remains subject to sanctions targeting the Government of Venezuela (GoV) and entities in which it holds a 50% or greater ownership interest, the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC) has issued a series of General Licenses (GLs) representing the broadest easing of Venezuela-related sanctions in years.
Benefits Blast
|February 17, 2026
|9 Min Read
Recent developments at the federal legislative and regulatory levels signal a significant shift toward greater transparency requirements in the pharmacy benefit management (PBM) industry.
Other Results 53 results
Site Content
Site Content
What Is Healthcare Privacy Law?
Today, healthcare privacy law is driven by the 1996 Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. This federal privacy rule establishes protections for specific patient health information. Healthcare plans, clearinghouses, and providers are subject to the law.
Site Content
Who Are Institutional Investors?
Institutional investors are large non-individual shareholders, including hedge funds, pension funds, mutual funds, endowment funds, and insurance companies.